The structure and ion channel activity of 6-benzylamino-3-hydroxyhexa-cyclo[6.5.0.0(3,7).0(4,12).0(5,10).0(9,13]tridecane

Arch Pharm (Weinheim). 2003 Apr;336(2):127-33. doi: 10.1002/ardp.200390009.

Abstract

A novel compound, 6-benzylamino-3-hydroxyhexacyclo [6.5.0.0(3, 7).0(4, 12).0(5, 10).0(9, 13)]-tridecane, was synthesized as part of an ongoing study to explore the ion channel activity of polycyclic cage amines. The known polycyclic calcium channel antagonist, 8-benzylamino-8, 11-oxapentacyclo [5.4.0.0(2, 6).0(3, 10).0(5, 9)]undecane (NGP 1-01) served as the lead compound and as a positive control for channel activity. The title compound inhibited calcium currents at test concentrations of 10 microM at depolarized membrane potentials (in the potential range where the L-type calcium channel inactivates). At the test concentrations modulating effects were also observed for sodium and the delayed rectifier potassium currents. Due to its activity at both Ca(2+) and Na(+) channels, this compound may offer utility as a cardiovascular and/or neuroprotecting agent.

Publication types

  • Comparative Study

MeSH terms

  • Animals
  • Bridged-Ring Compounds / chemistry
  • Bridged-Ring Compounds / pharmacology*
  • Calcium Channel Blockers / chemistry
  • Calcium Channel Blockers / pharmacology*
  • Calcium Channels, L-Type / drug effects
  • Calcium Channels, L-Type / physiology
  • Calcium Channels, T-Type / drug effects
  • Calcium Channels, T-Type / physiology
  • Delayed Rectifier Potassium Channels
  • Guinea Pigs
  • Heart / drug effects
  • Heart / physiology
  • Humans
  • Mass Spectrometry
  • Membrane Potentials / drug effects
  • Patch-Clamp Techniques
  • Potassium Channel Blockers / chemistry
  • Potassium Channel Blockers / pharmacology*
  • Potassium Channels / drug effects
  • Potassium Channels / physiology
  • Potassium Channels, Inwardly Rectifying / drug effects
  • Potassium Channels, Inwardly Rectifying / physiology
  • Potassium Channels, Voltage-Gated*
  • Sodium Channel Blockers / chemistry
  • Sodium Channel Blockers / pharmacology*
  • Sodium Channels / drug effects
  • Sodium Channels / physiology
  • Structure-Activity Relationship
  • Time Factors

Substances

  • 6-benzylamino-3-hydroxyhexa-cyclo(6.5.0.0(3,7).0(4,12).0(5,10).0(9,13) )tridecane
  • Bridged-Ring Compounds
  • Calcium Channel Blockers
  • Calcium Channels, L-Type
  • Calcium Channels, T-Type
  • Delayed Rectifier Potassium Channels
  • Potassium Channel Blockers
  • Potassium Channels
  • Potassium Channels, Inwardly Rectifying
  • Potassium Channels, Voltage-Gated
  • Sodium Channel Blockers
  • Sodium Channels